Mechanisms of Action of GLP-1 Agonists in T2D

April 29, 2019 12:36 pm

Expert colleagues react to the benefits demonstrated through data with the use of GLP-1 agonists for the treatment of type 2 diabetes and explore how the various options work.

Category: News
About The Author
-
Previous

GLP-1 Agonist Therapy in a Patient With T2D and CVD
Next

Type 2 Diabetes and Cardiovascular Disease: Risk Factors

Related Videos

Team-based-care-for-patients-with-T2D-and-kidney-disease-Katherine-R-Tuttle-Jay-H-Shubrook

Team-based care for patients with T2D and kidney disease | Katherine R Tuttle & Jay H Shubrook

EASD-2019-Personalised-Prevention-Of-CVD-In-T2D-Prof-Alessandro-Doria

EASD 2019 : Personalised Prevention Of CVD In T2D- Prof Alessandro Doria

Zanetti-et-al-Birthweight-T2D-and-Cardiovascular-Disease

Zanetti et al; Birthweight, T2D, and Cardiovascular Disease

Unleashing-the-Truth-How-to-Put-T2D-Patients-Hearts-First

Unleashing the Truth: How to Put T2D Patients’ Hearts First

Sodium-Glucose-Transporter-2-Inhibition-An-Important-Advancement-for-Patients-with-T2D-and-CKD

Sodium-Glucose Transporter-2 Inhibition: An Important Advancement for Patients with T2D and CKD

Hua-Medicine-A-Global-Effort-to-Stop-Diabetes

Hua Medicine – A Global Effort to Stop Diabetes